NIH Public Access
Author Manuscript
J Am Chem Soc. Author manuscript; available in PMC 2009 May 21.

Published in final edited form as:
J Am Chem Soc. 2008 May 21; 130(20): 6324–6325. doi:10.1021/ja801383f.

Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium *Leptolyngbya* sp.

Rebecca A. Medina[†], **Douglas E. Goeger**[†], **Patrice Hills**[‡], **Susan L. Mooberry**[‡], **Nelson Huang**[§], **Luz I. Romero**[||], **Eduardo Ortega-Barría**[||], **William H. Gerwick**[⊥], and **Kerry L. McPhail**[†]

†*College of Pharmacy, Oregon State University, Corvallis, OR 97331*

‡*Southwest Foundation for Biomedical Research, San Antonio, Texas 78227*

§*Chemical and Screening Sciences, Wyeth Research, Cambridge, MA 02140*

||*Instituto de Investigaciones Científicas Avanzados y Sevicios de Alta Tecnología, Clayton, Panama 5, Republic of Panama*

⊥*Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093*

Abstract

Coibamide A (**1**) is a new, potent antiproliferative depsipeptide which was isolated from a marine *Leptolyngbya* cyanobacterium collected from the Coiba National Park, Panama. The planar structure of **1** was elucidated by a combination of NMR spectroscopy and mass spectrometry. Exhaustive 1D and 2D NMR spectroscopy included natural abundance ^{15}N and variable temperature experiments; mass spectrometry included TOF-ESI-MS^n and FT-MS^n experiments. Chemical degradation followed by chiral HPLC- and GC-MS analyses was used to assign the absolute configuration of **1**. This highly methylated cyclized depsipeptide exhibited an unprecedented selectivity profile in the NCI 60 cancer cell line panel and appears to act via a novel mechanism.

Marine organisms continue to yield a diverse array of biologically active molecules, a remarkable number of which are peptide-based cancer cell toxins of putative microbial symbiont biogenesis.[1] Development of these as anticancer drugs has met with some success:[2] ascidian-derived dihydrodidemnin B (aplidin®) has orphan drug status for the treatment of multiple myeloma and acute lymphoblastic leukemia; green algal isolate kahalalide F, and TZT-1027, a synthetic analog of the cyanobacterial metabolite dolastatin 10, reached phase II clinical trials. Other important cyanobacterial peptide leads include the cryptophycins and curacin A,[3] and these organisms continue to produce a wealth of anticancer lead compounds.[4] The high degree of *N*-methylation of many of these cyanobacterial peptides may improve their druggability since *N*-methylation has been shown to improve pharmacological parameters such as lipophilicity, proteolytic stability and duration of action, properties for which regular peptides are notoriously poor and which limits their bioavailability.[5]

In the context of our International Cooperative Biodiversity Groups program (ICBG) based in Panama, which focuses on drug discovery, biodiversity conservation and sustainable economic growth, we have isolated a potent cancer cell toxin with an unprecedented selectivity profile in the NCI 60 cell line panel. This cyanobacterial depsipeptide, named coibamide A in tribute

kerry.mcphail@oregonstate.edu.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

to its discovery from the UNESCO World Heritage Site of Coiba National Park,[6] highlights the importance of conserving pristine, unexplored repositories of diverse marine organisms.

The marine filamentous cyanobacterium *Leptolyngbya* sp. was collected by hand using SCUBA from the Coiba National Park, Panama. A crude organic extract of this material was subjected to bioassay-guided fractionation *via* normal phase vacuum liquid chromatography (NP-VLC) using a stepped gradient of hexanes to EtOAC to MeOH. In preliminary biological activity screening, the 100% EtOAc eluting fraction was cytotoxic (IC_{50} 300 ng/mL) to NCI-H460 human lung tumor cells, and was also active against malaria, leishmaniasis and trypanosomal tropical disease parasites. This VLC fraction was separated by reversed-phase C_{18} solid phase extraction and isocratic HPLC to yield the optically active colorless oil ($[\alpha]_D$ -54.1) coibamide A (**1**, 6.3 mg).

The molecular composition of **1** was established as $C_{65}H_{110}O_{16}N_{10}$ from FT-MS data ($[M + H]^+$ *m/z* 1287.8156, Δ -0.2 mmu). The peptidic nature of **1** was evident from its complex ^1H NMR spectra in all solvents ($CDCl_3$, C_6D_6, DMSO, C_5D_5N). However, *N*-methyl conformations were minimized in $CDCl_3$ which showed numerous α-proton multiplets (4.75-6.02), overlapped methyl doublets (δ 0.75-1.15), mutually coupled aromatic proton doublets (δ 7.14, 6.76), a broad 2H amide proton signal (6.65), and deshielded singlets integrating to 12 methyl groups attached to heteroatoms (δ 2.34-3.77). The ^{13}C NMR spectra for **1** in $CDCl_3$ and C_6D_6 featured an indeterminate number of resonances, with numerous ester/amide carbonyl ^{13}C signals, due to localized symmetry (*O*-Me-Tyr, *N,N*-diMe-Val), steric constraints (*N*-Me-Thr), signal overlap and multiple conformations. These data suggested a high degree of *N*- and *O*-methylation, an observation supported by standard amino acid analysis which yielded only one alanine and one *O*-methyl tyrosine residue. These two amino acids, one hydroxy acid and eight *N*-methylated residues were assigned from 2D experiments ($CDCl_3$) including COSY, TOCSY, multiplicity-edited HSQC, HSQC-TOCSY, HMBC, H2BC[7] and ^1H-^{15}N gHMBC.

Elucidation of seven of the eight *N*-methylated residues began with HMBC correlations from each *N*-methyl singlet to the corresponding α-carbon, the side-chain spin systems of which were delineated by TOCSY experiments to give *N*-methylalanine, two *N*-methylleucines, *N*-methylisoleucine, two *N,O*-dimethylserines, and an *N,N*-dimethylvaline residue. The latter terminal residue was described by a 6H singlet ($\delta_{H\text{-}64/65}$ 2.34) that was HSQC-correlated to a prominent ^{13}C resonance ($\delta_{C\text{-}64/65}$ 41.3) and ^{15}N-gHMBC-correlated to a shielded ^{15}N resonance (δ_N 24.6). Fortunately, nine of ten N atoms in **1** were observed in the latter ^{15}N-gHMBC[8] experiment which showed additional correlations from five *N*-methyls to δ_N 105.6, 108.5, 113.4, 117.5, 120.5, two α-methyls (Ala and *N*-Me-Ala) to δ_N 115.1, 122.4, and H_2-7 of *O*-Me-Tyr to δ_N 118.2. Hydroxyisovaleric acid (HIV) was assigned on the basis of TOCSY correlations from deshielded CH-55 (δ_H 5.00, δ_C 74.7) to isopropyl methine ($\delta_{H\text{-}56}$ 2.21) and methyl ($\delta_{H3\text{-}57/58}$ 1.06) resonances. At this point, it remained to assign 114 mass units (interpreted as $C_5H_8O_2N$ = *N*-Me-Thr or *N,O*-diMe-Ser), to determine the carboxyl terminus and to establish the sequence of residues in the depsipeptide chain. COSY correlations were observed between an unassigned methyl doublet at δ 1.07 (H_3-40) and an oxygenated methine multiplet at δ 5.50 (H-39). Strong ROESY correlations, but no COSY or TOCSY correlations, were observed between this methyl-oxymethine pair and a very broad, partially obscured signal (δ 2.89, $CDCl_3$; 3.11 ppm, C_6D_6). Variable temperature experiments in $CDCl_3$ (298-328K, 700 MHz, 1 mm cryoprobe) resolved this broad peak into a 3H singlet which was HSQC-correlated to an *N*-methyl resonance ($\delta_{C\text{-}41}$ 29.7). Furthermore, careful examination of C_6D_6 HSQC data revealed an additional heteroatom-substituted methine ($\delta_{H\text{-}38}$ 6.72, $\delta_{C\text{-}38}$ 56.6), which showed weak TOCSY correlations to the above described methyl-oxymethine pair. Hence, the remaining residue was assigned as *N*-Me-Thr.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Two partial structures (Figure 1, **A** and **B**) could be assembled based on a combination of mass spectrometric data and ROESY correlations between each *N*-methyl and the α-proton of the adjacent residue. Additionally, a ROESY correlation between *N*-CH_3-36 and the *N*-Me-Thr β- and γ-protons (H-39, H_3-40) positioned this residue at the *N* terminus of partial structure **A**.

A ROESY correlation between γ-H_3-40 of the *N*-Me-Thr and α-H-43 (*N*-Me Leu) in combination with MS fragments of *m/z* 535 and 567 (Figure 1, **C**) oriented *N*-Me-Thr as the fifth residue in the depsipeptide backbone, thus linking partial structures **A** and **B**. This sequence of residues was also consistent with MS^2 fragments observed by LC-MS of the base hydrolysate of **1**, which comprised four major linear products (**2**-**5**, pS30). Finally, an HMBC correlation from H-39 to carbonyl C-1 (δ_C 170.4) indicated an ester linkage from *N*-Me-Thr to the C-terminal *N*-Me-Ala to complete the planar structure of coibamide A (**1**).

Acid hydrolysis of **1** followed by various HPLC-MS and GC-MS methodologies was used to determine the absolute configuration of coibamide A. While some standards were commercially available (*N*-Me-Leu, *N*-Me-Ile, *N*-Me-Ala, Ala, HIV and *O*-Me-Tyr), others required laboratory synthesis by standard methods (*N*-Me-Thr, *N,N*-diMe-Val, and *N,O*-diMe-Ser). Chiral HPLC (Phenomenex Chirex phase 3126 (D), 4.6 × 250 mm) established the presence of *O*-Me-L-Tyr, two *N,O*-diMe-L-Ser residues, *N,N*-diMe-L-Val, and L-Ala, while chiral GC-MS (CyclosilB, 30.0 m × 250 μm × 0.25 μm) of methylated standards and the natural product hydrolysate identified L-HIV. Treatment of the acid hydrolysate of **1** with Marfey's reagent, followed by C_{18} HPLC established the presence of *N*-Me-L-Ile, *N*-Me-L-Leu, *N*-Me-L-Ala, and either *N*-Me-L-Thr or *N*-Me-L-*allo*-Thr. The presence of *N*-Me-L-Thr is proposed from computational models[9] of the two possible coibamide structures, constrained by ROESY correlations between *N*-CH_3-4 and CH_3-40, and between α-H-2 and *N*-CH_3-48.

Coibamide A displayed potent cytotoxicity to NCI-H460 lung cancer cells and mouse neuro-2a cells ($LC_{50} < 23$ nM), but did not interfere with tubulin or actin in cytoskeletal assays. Flow cytometric studies showed that **1** caused a significant dose dependent increase in the number of cells in the G_1 phase of the cell cycle with little change in G_2/M and a loss of cells in S phase (see supporting information). Coibamide A was evaluated against the NCI's *in vitro* panel of 60 cancer cell lines, and produced mean cytostatic (GI_{50} and TGI with range) and cytotoxic (LC_{50} and range) parameters as follows: log GI_{50} -8.04 (2.96); log TGI - 5.85 (3.43); log LC_{50} -5.11 (2.66). These log mean values of < -4 with log range values of >2 indicate both potency and histological selectivity. Coibamide A showed highest potency (GI_{50}) to MDA-MB-231 (2.8 nM), LOX IMVI (7.4 nM), HL-60(TB) (7.4 nM) and SNB-75 (7.6 nM), and good histological selectivity for breast, CNS, colon and ovarian cancer cells (see supporting information). Coibamide A was COMPARE negative,[10] indicating that it likely inhibits cancer cell proliferation through a novel mechanism.

In summary, coibamide A (**1**) is a promising lead agent in cancer drug discovery, with a potentially new mechanism of action. Further investigation of the molecule is being pursued *via* chemical synthesis, since the producing organism has not been cultured successfully in the laboratory to date.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

Financial support from the NIH Fogarty International Center (ICBG grant TW006634) and NCI (CA52955), and from the William Randolph Hearst Foundation (to SLM) is gratefully acknowledged. We thank the Smithsonian Tropical

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Research Institute, crew of R/V Urraca, T. Capson, C. Guevara and R. Thacker for collection of the cyanobacterium, and Autoridad Nacional del Ambiente (ANAM), Panama, for permission to make this collection, OSU Biochemistry NMR Facility for 600 MHz spectrometer time, J. Morre and the OSU EIHS Center for MS data acquisition (NIEHS P30 ES00210), Prof. F. D. Horgen for *N,O*-diMeSer standards, and C. Anklin (Bruker Biospin) for 700 MHz NMR data.

References

(1). Simmons TL, Coates RC, Clark BR, Engene N, Gonzalez D, Esquenazi E, Dorrestein PC, Gerwick WH. Proc. Natl. Acad. Sci U.S.A 2008;105:4587–4594. [PubMed: 18250337]

(2). Rawat DS, Joshi MC, Joshi P, Atheaya H. Anti-Cancer Agents Med Chem 2006;6:33–40.

(3). Gerwick WH, Tan LT, Sitachitta N. Alkaloids 2001;57:75–184. [PubMed: 11705123]

(4). Tan LT. Phytochemistry 2007;68:954–979. [PubMed: 17336349]

(5)(a). Loffert AJ. Pept. Sci 2002;8:1–7. (b) Morishita M, Peppas NA. Drug Discov. Today 2006;11:905–910. [PubMed: 16997140]

(6). Coiba National Park. http://whc.unesco.org/en/list/1138

(7). Nyberg NT, Duus JØ, Sørensen OW. J. Am. Chem. Soc 2005;127:6154–6155. [PubMed: 15853304]

(8). Martin GE, Hadden CE. J. Nat. Prod 2000;63:543–585. [PubMed: 10785437]

(9). Macromodel 9.1, see supporting information, pS6.

(10). Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. J. Natl. Cancer Inst 1989;81:1088–1092. [PubMed: 2738938]

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 1.
Partial structures **A** and **B** assembled from key ROESY correlations and mass fragments; **C**. Key mass spectrometric fragments supporting the position of *N*-Me-Thr and cyclization of **1**.